Search clinical trials for: Multiple Myeloma

Total 12812 results

Dickran Kazandjian, MD
Regeneron Pharmaceuticals

Not yet recruiting

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (IMMUNOPLANT)

Multiple Myeloma

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Not yet recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Peking University People's Hospital

Not yet recruiting

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Relapsed/Refractory Multiple Myeloma

China
Tufts Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
Wuhan Union Hospital, China

Not yet recruiting

Study of SYS6020 in BCMA-positive Multiple Myeloma

Multiple Myeloma
Bristol-Myers Squibb

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy

Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukaemia

Belgium
Sanofi

Not yet recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (SubQSA)

Plasma Cell Myeloma Refractory
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
Jack Khouri

Not yet recruiting

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Multiple Myeloma | Refractory Multiple Myeloma | Cytokine Release Syndrome | Immune Effector Cell Associated Neurotoxicity Syndrome

United States
Adriana Rossi

Not yet recruiting

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Early Assessment of Cardiac Function After Treatment With CAR-T Cells (Cardio CAR-T)

Lymphoma, B-Cell | Multiple Myeloma | Acute Lymphoblastic Leukemia | Hematologic Malignancy | Car T- Cell

France
Thomas Martin, MD
Bristol-Myers Squibb; Janssen Research & Development, LLC

Not yet recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Washington University School of Medicine
National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital

Recruiting

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Multiple Myeloma | Rectal Cancer | Cholangiocarcinoma | Colon Cancer

United States
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)

Not yet recruiting

Precision Medicine Study

Multiple Myeloma

United States
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Multiple Myeloma | Primary Plasma Cell Leukemia
Emory University
National Cancer Institute (NCI); National Center for Complementary and Integrative...

Recruiting

Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation

Lymphoma | Multiple Myeloma

United States
Senti Biosciences

Not yet recruiting

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

AML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological Malignancies
Jinling Hospital, China

Recruiting

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Newly Diagnosed Multiple Myeloma

China
The Christie NHS Foundation Trust
CellCentric Ltd.

Not yet recruiting

PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma (iPREFER)

Multiple Myeloma

United Kingdom
Leuko Labs, Inc.

Not yet recruiting

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia (PC002)

Multiple Myeloma | Diffuse Large B Cell Lymphoma
RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
Cartesian Therapeutics

Recruiting

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (DC15-MM-01)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Multiple Myeloma
Guangdong Second Provincial General Hospital

Not yet recruiting

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Multiple Myeloma

United States, Canada
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics (DISCOVERY)

Lymphoma | Leukemia | Multiple Myeloma | Hematologic Malignancies | Blood Cancers

United States
Biocad

Recruiting

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma (DARVIVA)

Multiple Myeloma

Russian Federation
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (LINKER-AL2)

Relapsed/Refractory Systemic Light Chain Amyloidosis
Siriraj Hospital
Faculty of Medicine Siriraj Hospital

Not yet recruiting

Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease (Haplo)

Multiple Myeloma
Janssen-Cilag Ltd.

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (REALiTEC)

Relapsed/Refractory Multiple Myeloma (RRMM)

Spain, France
Siriraj Hospital
Faculty of Medicine Siriraj Hospital

Not yet recruiting

Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room (Step down ward)

Multiple Myeloma
Hospital General de Mexico

Recruiting

Two Schemes Response in Multiple Myeloma

Survivorship | Response, Acute Phase

Mexico
PETHEMA Foundation

Recruiting

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Multiple Myeloma in Relapse

Spain
University of Alberta

Not yet recruiting

Prehab Prior to Stem Cell Transplantation in Multiple Myeloma (MOTIVATE)

Multiple Myeloma | Exercise | Prehabilitation

Canada
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Soochow University

Recruiting

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
University of Chicago

Not yet recruiting

Hypofractionation (Radiation) Trial for Multiple Myeloma

Multiple Myeloma

United States
OriCell Therapeutics Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Cardiovascular Diseases | Vascular Diseases | Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Immunoproliferative Disorders | Hematologic Diseases | Hemostatic Disorders | Hemorrhagic Disorders | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood...

United States
University Hospital, Angers

Not yet recruiting

RAT-HEMATO : Return to Work After Malignant Hemopathy (RAT-HEMATO)

Lymphoma | Leukemia | Multiple Myeloma

France
Academic Centre for Dentistry in Amsterdam

Not yet recruiting

LI-TASTE Study: Light for Taste (LI-TASTE)

Multiple Myeloma
Sohag University

Not yet recruiting

Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality

Hematological Malignancies
Centro di Riferimento Oncologico - Aviano

Recruiting

Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse

Multiple Myeloma

Italy
Shanxi Bethune Hospital

Recruiting

Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM

Multiple Myeloma in Relapse

China
FengYan Jin
Sun Yat-sen University; Shandong Cancer Hospital and Institute; Affiliated Hospital... and other collaborators

Not yet recruiting

Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma

Multiple Myeloma | First Relapse
University Health Network, Toronto
Janssen Inc.

Not yet recruiting

Plan Development for Giving Teclistamab in the Outpatient Setting

Multiple Myeloma | Relapsed Cancer | Refractory Cancer
Hospital Universitari Vall d'Hebron Research Institute
ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases

Recruiting

European Rare Blood Disorders Platform (ENROL) (ENROL)

Leukemia | Anemia | Iron Metabolism Disorders | Anemia, Sickle Cell | Thalassemia | Bleeding Disorder | Myeloma | Lymphoid Neoplasm | Blood Cancer | Bone Marrow Failure | Red Cell Membrane and Enzyme Abnormalities | Myeloma, Malignant

Spain
Uppsala University
Dalarna County Council, Sweden; Uppsala County Council, Sweden

Not yet recruiting

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Myeloma Multiple
University Hospital, Toulouse

Not yet recruiting

ICOPE Program Feasibility in the Management of Myeloma Patients (Onco-ICOPE)

Multiple Myeloma | Frailty

France
Affiliated Hospital of Nantong University

Recruiting

Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma

Multiple Myeloma

China
Shahid Beheshti University of Medical Sciences

Not yet recruiting

Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Refractory

Iran, Islamic Republic of

Search clinical trials for: Multiple Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations